Literature DB >> 21623182

The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies.

Oksana Yaskiv1, Xiaochun Zhang, Kelly Simmerman, Tom Daly, Huiying He, Sara Falzarano, Longwen Chen, Cristina Magi-Galluzzi, Ming Zhou.   

Abstract

Diagnosis of limited cancer can be challenging in prostate needle biopsies, and immunohistochemistry is commonly used in such settings. Recently, TMPRSS2:ERG gene rearrangement was found to be highly specific for and detected in approximately 50% of prostate cancer. Positive immunohistochemical staining with a novel anti-ERG antibody highly correlated with TMPRSS2:ERG gene rearrangement status. We developed a double immunohistochemical staining containing both erythroblastosis virus E26 oncogen (ERG) and basal cell marker P63 antibodies and evaluated its use in the diagnosis of limited cancer in prostate needle biopsies. A total of 77 prostate needle biopsies containing cancer occupying <1 mm of the length of only 1 core of the entire biopsy set were stained with the double stain containing ERG and P63 antibodies. ERG positivity and its staining intensity in cancerous and other noncancerous lesions were evaluated. ERG expression was detected in 42% (32 of 77) of cases, with strong, moderate, and weak staining intensity in 72%, 16%, and 12% of cases. The staining was uniform in 84% of cases and heterogeneous in 16% of cases with different staining intensities in >10% of cancerous cells. High-grade prostatic intraepithelial neoplasia was present in 17 cases, and in 5 (29%) cases ERG was positive in high-grade prostatic intraepithelial neoplasia glands, which were all immediately adjacent to or intermingled with ERG-positive cancerous glands. In 4 additional cases, positive ERG staining was found in morphologically benign glands, which were also immediately adjacent to or intermingled with ERG-positive cancerous glands. All other benign lesions distant from cancerous glands, including simple and partial atrophy, were negative for ERG. P63 was negative in all cancerous glands and positive in noncancerous lesions. The P63/ERG double immunostain combines the high sensitivity of P63 and the high specificity of ERG and may be potentially useful in the work-up of difficult prostate biopsies. The high specificity of ERG for the presence of cancer may have important implications for prostate biopsy interpretation and needs to be further validated in larger prospective studies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21623182     DOI: 10.1097/PAS.0b013e318215cc03

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  20 in total

1.  High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.

Authors:  Adrian Box; Mohammed Alshalalfa; Samar A Hegazy; Bryan Donnelly; Tarek A Bismar
Journal:  Tumour Biol       Date:  2016-06-07

Review 2.  ERG expression in prostate cancer: biological relevance and clinical implication.

Authors:  Hatem Abou-Ouf; Liena Zhao; Tarek A Bismar
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-28       Impact factor: 4.553

3.  Prostate cancer in Jordanian-Arab population: ERG status and relationship with clinicopathologic characteristics.

Authors:  Najla Aldaoud; Nour Abdo; Samir Al Bashir; Mohammad Alqudah; Noor Marji; Hiba Alzou'bi; Rami Alazab; Kiril Trpkov
Journal:  Virchows Arch       Date:  2017-05-26       Impact factor: 4.064

Review 4.  Clinical potential of the ERG oncoprotein in prostate cancer.

Authors:  Philip Rosen; Isabell A Sesterhenn; Stephen A Brassell; David G McLeod; Shiv Srivastava; Albert Dobi
Journal:  Nat Rev Urol       Date:  2012-02-14       Impact factor: 14.432

5.  Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies.

Authors:  Scott A Tomlins; Nallasivam Palanisamy; Javed Siddiqui; Arul M Chinnaiyan; Lakshmi P Kunju
Journal:  Arch Pathol Lab Med       Date:  2012-08       Impact factor: 5.534

6.  ERG expression and prostatic adenocarcinoma.

Authors:  Montse Verdu; Isabel Trias; Ruth Roman; Natalia Rodon; Beatriz Garcia-Pelaez; Miquel Calvo; Arturo Dominguez; Josep M Banus; Xavier Puig
Journal:  Virchows Arch       Date:  2013-05-24       Impact factor: 4.064

7.  Prognostic potential of ERG (ETS-related gene) expression in prostatic adenocarcinoma.

Authors:  A Marcell Szász; Attila Majoros; Philip Rosen; Shiv Srivastava; Albert Dobi; Attila Szendrői; Janina Kulka; Péter Nyirády
Journal:  Int Urol Nephrol       Date:  2013-05-18       Impact factor: 2.370

8.  ERG and PTEN status of isolated high-grade PIN occurring in cystoprostatectomy specimens without invasive prostatic adenocarcinoma.

Authors:  Carlos L Morais; Liana B Guedes; Jessica Hicks; Alexander S Baras; Angelo M De Marzo; Tamara L Lotan
Journal:  Hum Pathol       Date:  2016-05-14       Impact factor: 3.466

9.  Usefulness of a monoclonal ERG/FLI1 antibody for immunohistochemical discrimination of Ewing family tumors.

Authors:  Scott A Tomlins; Nallasivam Palanisamy; J Chad Brenner; Jennifer N Stall; Javed Siddiqui; Dafydd G Thomas; David R Lucas; Arul M Chinnaiyan; Lakshmi P Kunju
Journal:  Am J Clin Pathol       Date:  2013-06       Impact factor: 2.493

Review 10.  Evaluation of the TMPRSS2:ERG fusion for the detection of prostate cancer: a systematic review and meta-analysis.

Authors:  Yanhong Yao; Haitao Wang; BaoGuo Li; Yong Tang
Journal:  Tumour Biol       Date:  2013-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.